BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Jenscare’s LuX-Valve Plus Approved for Use in Greater Bay Area Under Hong Kong-Macao Medicine and Equipment Connect

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease ...

October 13, 2025 | News

IHH Healthcare Launches Global Incubator Programme to Empower Early-Stage Startups

By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthc...

October 13, 2025 | News

Roche and OASES Partner to Advance Healthcare Innovation in Hong Kong

Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and stre...

October 13, 2025 | News

HKUST Uncovers Genetic Variant Driving Alzheimer’s Risk Among Ethnic Chinese

A landmark study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, TREM2 ...

October 06, 2025 | News

Health Hope Pharma and Hanmi Grant Gilead Global Rights to Encequidar in Virology

Health Hope Pharma Limited announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for ence...

September 30, 2025 | News

Akeso Doses First Patient in Phase II Study of Novel TIGIT/TGF-β Bifunctional Antibody for Pancreatic Cancer

Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independent...

September 23, 2025 | News

Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...

September 16, 2025 | News

Innorna completes Phase II enrollment for IN006, the first bivalent RSV mRNA vaccine

Innorna announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory...

September 11, 2025 | News

Sirnaomics Secures HKD 138 Million Strategic Investment from Bloomage Biotech

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, announced that it has entered into a ...

September 09, 2025 | News

China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer

Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...

September 03, 2025 | News

Akeso Reports Positive Phase 3 Results For Gumokimab In Ankylosing Spondylitis And Manfidokimab In Atopic Dermatitis

Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025

The first eight months of 2025 have been transformative for biosupplier technologies worldwide. From innovative lab reagents and biomaterials to ad...

August 22, 2025 | Analysis

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

Stay Connected